PROTECT PATIENTS. STOP 340B CUTS!
What is 340B?
Section 340B of the U.S. Public Health Service Act provides that drug manufacturers that choose to participate in Medicare and Medicaid sell certain outpatient drugs to eligible safety-net providers at a discount. These providers then use the savings to “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” Learn more about 340B.
Drug Manufacturers are Refusing to Provide Required 340B Discounts
Five major drug manufacturers – Eli Lilly, AstraZeneca, Sanofi, Novo Nordisk, and United Therapeutics – have unilaterally stopped providing required 340B discounts when drugs are dispensed at community pharmacies. Novartis has stopped providing 340B pricing to hospitals on drugs dispensed at community pharmacies that are more than 40 miles away from the hospitals’ parent sites. Merck is threatening similar actions against hospitals that do not hand over patient claims data.
These actions are in violation of the 340B statute, which states that manufacturers “must provide” 340B pricing on any eligible drug to any eligible covered entity regardless of how the hospital intends to dispense the drug.
Without access to 340B discounts, millions of patients could be at risk of losing access to a wide range of services they rely on to stay healthy.
We are calling on the U.S. Department of Health and Human Services to use its authority to put a stop to these harmful actions and protect patients and the providers who care for them.
Six national organizations, representing hospitals and pharmacists, along with three 340B hospitals have filed a joint lawsuit demanding prompt action to stop drug companies that are refusing to provide 340B discounts for covered drugs dispensed at community pharmacies. Read the legal complaint here.
On December 30, 2020 the Office of the HHS General Counsel released an advisory opinion that drug manufacturers are obligated to provide 340B pricing to covered entities on drugs dispensed at community-based pharmacies. Read 340B Health's statement about the advisory opinion here.
Stories of How 340B Hospitals Use Community-based Pharmacy Partnerships to Benefit Patients
- Chicago Tribune - Eli Lilly, other Big Pharma firms are making it harder for low-income patients to get discount drugs under federal program, doctors say
- The New York Times - Drug Makers Are Pulling Back From a Program to Help the Needy
- The Hill - Unconscionable drug company efforts threaten communities hit hardest by COVID-19
- Read a letter from seven national organizations to HHS.
- Read a letter from more than 1,100 safety-net hospitals participating in 340B to HHS.
- Read a letter from a bipartisan group of 28 U.S. senators to HHS.
- Read a letter from a bipartisan group of more than half of the members of the U.S. House of Representatives to HHS.
- Read a letter from more than 60 advocacy groups for patients and social justice to HHS.
- Read a letter from a bipartisan group of 29 state attorneys general to HHS.
- Read how Eli Lilly reaped a 22% revenue increase in the fourth quarter of 2020, partially by refusing 340B discounts to safety-net hospitals.